Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Shanghai Rendu Biotechnology Co., Ltd.

Market Cap 2.17B 320M 279M 259M 243M 454M 30.21B 457M 3.07B 1.19B 14.89B 1.2B 1.18B 51.71B P/E 2024
-179x
P/E 2025 186x
Enterprise Value 1.35B 200M 174M 162M 151M 284M 18.86B 285M 1.92B 743M 9.3B 751M 735M 32.29B EV / Sales 2024
3.31x
EV / Sales 2025 6.55x
Free-Float
42.43%
Yield 2024
0.56%
Yield 2025 2.38%
05-14 Shanghai Rendu Biotechnology's share trade to resume from May 15 RE
05-13 Nanjing Haijing Pharmaceutical Co., Ltd. agreed to acquire 21.25% stake in Shanghai Rendu Biotechnology Co., Ltd. from Ju Jinliang, Qiming Weichuang Venture Capital Management Company Limited, Runcong Enterprise Management Center (Limited Partnership), China International Capital Corporation Limited, Qiming Ventures Fund III, Changzhou Jinxin Venture Capital Co., Ltd. and Novel Praise Limited for approximately CNY 520 million. CI
05-08 Rendu Biotech's Controlling Shareholder Eyes Share Transfer Deal MT
05-07 Trading in Shanghai Rendu Biotechnology's shares to halt RE
04-28 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-10-30 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-04-29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-02-27 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-10-29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
24-08-29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 CI
24-08-19 Tranche Update on Shanghai Rendu Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 19, 2024. CI
1 day+6.92%
1 week+7.31%
Current month+13.64%
1 month+2.87%
3 months+14.34%
6 months+10.93%
Current year+15.59%
1 week 50.66
Extreme 50.66
56.33
1 month 47.01
Extreme 47.01
56.66
Current year 45.58
Extreme 45.58
63.56
1 year 37.94
Extreme 37.94
63.56
3 years 22.5
Extreme 22.5
63.56
5 years 22.5
Extreme 22.5
72
10 years 22.5
Extreme 22.5
72
Manager TitleAgeSince
Chief Executive Officer 43 2022-12-08
Chief Tech/Sci/R&D Officer 60 2007-06-12
Director of Finance/CFO 52 2015-07-31
Director TitleAgeSince
Chairman 60 2007-06-12
Director/Board Member 43 2008-04-30
Director/Board Member 61 2020-10-20
Change 5-day change 1-year change 3-year change Capi.($)
+6.92%+7.31%+46.63%+32.39% 320M
+2.07%+0.12%+168.17%+253.96% 17.47B
+2.15%+1.85%-42.64%-22.56% 9.33B
+0.65%-0.63%+31.15%+11.83% 6.76B
+3.42%+2.78%-32.22% - 5.22B
-1.64%-3.63%-27.65%-32.78% 4.88B
+10.00%+20.71%+105.80%+104.59% 4.54B
+8.17%+20.51%+221.51%-39.98% 4.41B
+2.07%-2.17%-31.05%-33.48% 3.95B
-1.74%-2.46%-17.42%-43.06% 2.57B
Average +3.21%+4.41%+42.23%+25.66% 5.95B
Weighted average by Cap. +2.66%+3.20%+63.12%+77.66%

Financials

2024 2025
Net sales 177M 26.2M 22.86M 21.16M 19.84M 37.15M 2.47B 37.4M 251M 97.32M 1.22B 98.35M 96.24M 4.23B 162M 23.93M 20.88M 19.33M 18.11M 33.92M 2.26B 34.15M 229M 88.86M 1.11B 89.81M 87.88M 3.86B
Net income -7.81M -1.15M -1.01M -932K -874K -1.64M -109M -1.65M -11.07M -4.29M -53.65M -4.33M -4.24M -186M 10.09M 1.49M 1.3M 1.2M 1.13M 2.11M 141M 2.13M 14.29M 5.54M 69.28M 5.59M 5.47M 241M
Net Debt -798M -118M -103M -95.17M -89.21M -167M -11.11B -168M -1.13B -438M -5.48B -442M -433M -19.02B -815M -120M -105M -97.2M -91.11M -171M -11.35B -172M -1.15B -447M -5.59B -452M -442M -19.43B
Logo Shanghai Rendu Biotechnology Co., Ltd.
Shanghai Rendu Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production, and sales of molecular diagnostic reagents and equipment. The Company mainly operates three businesses. The reagent business is mainly engaged in the research, development, production, and sales of molecular diagnostic reagents for reproductive tract infections, respiratory tract infections, enteroviruses, and bloodborne infectious diseases, as well as other reagent products such as sample preservation solutions and nucleic acid extraction reagents. The instrument business is mainly engaged in the research, development, production, and sales of molecular diagnostic instruments such as the fully automated nucleic acid detection and analysis system (AutoSAT). The testing business is mainly engaged in the provision of clinical testing services, including pathogen detection for the genitourinary system, bloodborne pathogens, respiratory system, and digestive system.
Employees
239
Date Price Change Volume
26-06-18 55.91 ¥ +6.92% 1,136,763
26-06-17 52.29 ¥ -0.49% 596,449
26-06-16 52.55 ¥ +1.21% 562,915
26-06-15 51.92 ¥ -0.35% 862,731
  1. Stock Market
  2. Stocks
  3. 688193 Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!